PET tracer predicts tau pathology and AD, according to company press release.
Study links changes in the retina’s microvasculature to brain amyloid in cognitively normal adults.
What's the use of measuring neurofilament light in blood? The marker could help with AD trial enrollment and measuring drug effects. It could even guide brain-sparing improvements in heart surgery, say researchers at AAIC 18.
With buckets of new data at AAIC, blood NfL grabbed attention as a telltale of neurodegeneration. The protein predicts progression, and might one day track treatment effects.
At AAIC, competitors vied for advantage, and discussion moved swiftly to the issue of assay standardization.
Sensitive cognitive tests detect deficits in preclinical Alzheimer’s even before an amyloid scan reads positive. And CSF Aβ42 drops a decade before that—pushing research ever farther into the preclinical phase.
In early Parkinson’s disease, sparse areas on the retina correlate with dying dopaminergic neurons in the substantia nigra.
UCB-J hints at early synaptic loss in the hippocampus, but not the cortex. Researchers puzzle over the pattern.
Investors pledge new money for research into biomarkers that yield marketable tests.
In an unselected cohort, amyloid-PET scans changed clinical diagnoses and treatment plans for a quarter of participants.
High vascular risk scores and Aβ burden independently associate with cognitive decline, but combined, they speed things up.
ApoE4 raises CSF tau more in women than in men, suggesting sex may influence the risk of neurodegeneration, especially in amyloid-positive E4 carriers.
For the first time, NIA-AA proposal bases diagnosis in living people solely on biomarkers for plaques and tangles.
An infrared spectral signature of amyloid β-sheets predicted AD conversion years before diagnosis.
At AAT-AD/PD, scientists showed that correlated amyloid patches are an even earlier marker than brain-wide positivity, while others puzzled over why tau signals are lower in older people.